<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39340505</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2405-5018</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>JACC. Clinical electrophysiology</Title><ISOAbbreviation>JACC Clin Electrophysiol</ISOAbbreviation></Journal><ArticleTitle>Enhanced Ca<sup>2+</sup>-Driven Arrhythmogenic Events in Female Patients With Atrial Fibrillation: Insights From Computational Modeling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S2405-500X(24)00717-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacep.2024.07.020</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Substantial sex-based differences have been reported in atrial fibrillation (AF), but the underlying mechanisms are poorly understood.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study sought to gain a mechanistic understanding of Ca<sup>2+</sup>-handling disturbances and Ca<sup>2+</sup>-driven arrhythmogenic events in male vs female atrial cardiomyocytes and establish their responses to Ca<sup>2+</sup>-targeted interventions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We integrated reported sex differences and AF-associated changes (ie, expression and phosphorylation of Ca<sup>2+</sup>-handling proteins, cardiomyocyte ultrastructural characteristics, and dimensions) into our human atrial cardiomyocyte model that couples electrophysiology with spatially detailed Ca<sup>2+</sup>-handling processes. Sex-specific responses of atrial cardiomyocytes to arrhythmia-provoking protocols and Ca<sup>2+</sup>-targeted interventions were evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Simulated quiescent cardiomyocytes showed increased incidence of Ca<sup>2+</sup> sparks in female vs male myocytes in AF, in agreement with previous experimental reports. Additionally, our female model exhibited elevated propensity to develop pacing-induced spontaneous Ca<sup>2+</sup> releases (SCRs) and augmented beat-to-beat variability in action potential (AP)-elicited Ca<sup>2+</sup> transients compared with the male model. Sensitivity analysis uncovered distinct arrhythmogenic contributions of each component involved in sex and/or AF alterations. Specifically, increased ryanodine receptor phosphorylation emerged as the major SCR contributor in female AF cardiomyocytes, whereas reduced L-type Ca<sup>2+</sup> current was protective against SCRs for male AF cardiomyocytes. Furthermore, simulated Ca<sup>2+</sup>-targeted interventions identified potential strategies (eg, t-tubule restoration, and inhibition of ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca<sup>2</sup>⁺-ATPase) to attenuate Ca<sup>2+</sup>-driven arrhythmogenic events in women, and revealed enhanced efficacy when applied in combination.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sex-specific modeling uncovers increased Ca<sup>2+</sup>-driven arrhythmogenic events in female vs male atria in AF, and suggests combined Ca<sup>2+</sup>-targeted interventions are promising therapeutic approaches in women.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xianwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA. Electronic address: https://twitter.com/xianweizhang1.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yixuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Charlotte E R</ForeName><Initials>CER</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA. Electronic address: https://twitter.com/Char_Smith3.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Louch</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway. Electronic address: https://twitter.com/IEMRLouch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morotti</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA. Electronic address: https://twitter.com/MorottiLab.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobrev</LastName><ForeName>Dobromir</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen, Essen, Germany; Montréal Heart Institute, Université de Montréal, Montréal, Québec, Canada; Department of Integrative Physiology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: https://twitter.com/dr_dobrev.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grandi</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA. Electronic address: ele.grandi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ni</LastName><ForeName>Haibo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of California Davis, Davis, California, USA. Electronic address: hbni@ucdavis.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 OD026580</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL170521</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Clin Electrophysiol</MedlineTA><NlmUniqueID>101656995</NlmUniqueID><ISSNLinking>2405-500X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2024 Mar 13:2024.03.04.583217. doi: 10.1101/2024.03.04.583217</RefSource><PMID Version="1">38496584</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ca(2+)-driven arrhythmias</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">computational modeling</Keyword><Keyword MajorTopicYN="N">sex differences</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>Funding Support and Author Disclosures This work was supported by American Heart Association Career Development Award 24CDA1258695 (to Dr Ni), Postdoctoral Fellowships 20POST35120462 (to Dr Ni), 24POST1195229 (to Dr Wu), and Predoctoral Fellowship 20PRE35120465 (to Dr Zhang); National Institutes of Health/National Heart, Lung, and Blood Institute grants R01HL131517 (to Drs Grandi, Louch, and Dobrev), R01HL170521 (to Drs Grandi and Ni), R01HL141214 and P01HL141084 (to Dr Grandi), R01HL136389 (to Dr Dobrev), R01HL089598 (to Dr Dobrev), R01HL163277 (to Dr Dobrev), R01HL160992 (to Dr Dobrev), R01HL165704 (to Dr Dobrev), and R00HL138160 (to Dr Morotti); National Institutes of Health Stimulating Peripheral Activity to Relieve Conditions Grant 1OT2OD026580-01 (to Dr Grandi); the Research Council of Norway (Grant No. 287395 to Dr Louch); UC Davis School of Medicine Dean’s Fellow Award (to Dr Grandi); the European Union (large-scale integrative project MAESTRIA, No. 965286, to Dr Dobrev); and the Burroughs Wellcome Fund–Doris Duke Charitable Foundation "COVID-19 Fund to Retain Clinical Scientists" Award (to Dr Morotti). All authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>10</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39340505</ArticleId><ArticleId IdType="doi">10.1016/j.jacep.2024.07.020</ArticleId><ArticleId IdType="pii">S2405-500X(24)00717-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle>